Company profileMixed portfolio#876 of 1,318 in Pakistan✓ No DRAP alerts

Reckitt Benckiser Pak Ltd.

Mixed portfolio · 15 pharmaceutical brands of 7 registrations

Ranked #54 of 100 companies in Gastro

7 registered products 15 pharmaceutical brands 12 distinct molecules 0 DRAP alerts
Part of this company's portfolio (“Eye”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

7
registered products
15
pharmaceutical brands
12
distinct molecules
10
therapeutic classes
0
DRAP alerts

Reckitt Benckiser Pak Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 7 product registrations across 12 distinct molecules. Its portfolio is concentrated in Gastro and Stomatologicals Preparations. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Reckitt

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Gentamicin3 brands
Eye2 brands
Ear2 brands
Vgentamycin Base 300 U1 brand
Gentamicin 0.35W1 brand
Gentamicin Inj1 brand
Gentamicin ...... 80 Mg1 brand

Therapeutic classes

Gastro · 2Stomatologicals Preparations · 1Allergy · 1Anti-Infective, Ophthalmologicals · 1Ear Conditions · 1Anti-Infectives · 1Aminoglycoside Antibacterials · 1Fever/Flu/Cough · 1Eye Conditions · 1Antiinflammatory Agents And Antiinfectives In Combination · 1

Conditions treated

Ulcer/Reflux/Flatulence/Acidity · 2Oral Allergy/Infections · 1Infection/Pain · 1General Infections · 1Cold/Cough/Sore Throat · 1Allergy/Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official3 products · Rs 51.14 – Rs 118.66
DVAGO2 products · Rs 48.73 – Rs 57.75
Servaid8 products · Rs 34.08 – Rs 1,350
Median across source: Rs 63.02

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.3 shared molecules
INNVOTEK PHARMACEUTICALS3 shared molecules
VALOR PHARMACEUTICALS3 shared molecules
EPOCH PHARMACEUTICAL3 shared molecules
Merck Marker (Pvt) Ltd.3 shared molecules
ALZA Pharma3 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
NABIQASIM INDUSTRIES (PVT) LTD. holds 196 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
INNVOTEK PHARMACEUTICALS holds 44 molecules not in this portfolio
AcetazolamideAcyclovirArtemetherAscorbic AcidAzithromycinBisoprolol

Get the full profile for Reckitt

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.